Welcome to our dedicated page for Marex Group SEC filings (Ticker: MRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Marex Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Marex Group's regulatory disclosures and financial reporting.
Marex Group plc officer Paolo Tonucci reported selling 16,666 Ordinary Shares of the company in open-market transactions. The sales took place on June 15, 2026 at weighted average prices around the low $60s, with individual trade prices ranging from $60.945 to $63.075.
The filing notes these trades were executed under a pre-arranged Rule 10b5-1 trading plan entered into on October 22, 2025, indicating they were scheduled in advance. Tonucci’s reported holdings include 220,746 ordinary shares underlying deferred bonus plan awards that convert into one ordinary share each upon vesting and settlement.
Marex Group plc Chief Executive Officer Ian T. Lowitt reported open-market sales of a total of 37,143 Ordinary Shares on June 12, 2026, executed under a pre-arranged Rule 10b5-1 plan. The shares were sold at weighted average prices in the low-$60s per share.
Following these transactions, Lowitt directly holds 2,831,358 Ordinary Shares, which includes 194,411 shares underlying deferred bonus plan awards that represent contingent rights to receive one share each upon vesting and settlement.
MRX affiliate submitted a Form 144 notice to sell Common Stock. The filing lists proposed and recent sales by Paolo Tonucci, including transactions of 16,666–16,668 shares on 02/23/2026, 03/16/2026, 04/13/2026, and 05/11/2026 with reported proceeds shown.
Marex Group plc is offering $300,000 of Autocallable Fixed Income Notes with Absolute Return Buffer linked to the worst performing common stock of Apple (AAPL), Coherent (COHR) and Morgan Stanley (MS). Each Note has a $1,000 principal amount, a quarterly fixed interest payment of $30.00 (3.00% per quarter; 12.00% per annum) and an Estimated Initial Value of $948.90 per Note on the Trade Date. The Notes can be automatically called on specified Call Observation Dates if each underlying closes at or above its Call Threshold; otherwise payment at maturity depends on the Reference Return of the Worst Performing Underlying with a 50.00% buffer and a Downside Leverage Factor of 200%. The offering price to public is $1,000.00 per Note; proceeds to issuer are $975.00 per Note. The Notes are senior unsecured obligations of Marex and are subject to Marex credit risk, limited liquidity, and the detailed risk factors described in the supplement.
MRX: a Form 144 notice lists proposed sales of Common Stock by an issuer insider.
The filing shows proposed sell quantities tied to compensation grants: 29,769 shares with a 03/10/2025 grant date and 7,374 shares with a 05/19/2025. The broker listed is J.P. Morgan Securities LLC.
Marex Group plc is offering Autocallable Fixed Income Notes with Absolute Return Buffer linked to the worst performing of AAPL, COHR and MS. Each Note has a $1,000 principal amount, quarterly fixed interest equal to 3.00% per quarter (12.00% per annum), an expected Estimated Initial Value between $920.00 and $960.00, a Final Valuation Date of December 13, 2027 and a Maturity Date of December 20, 2027.
The Notes pay quarterly interest and are subject to an automatic call if each Underlying is at or above its Call Threshold on a Call Observation Date. At maturity, payments depend on the Reference Return of the Worst Performing Underlying, a 50.00% Buffer Amount, and a Downside Leverage Factor of 200%, exposing holders to potential loss of up to 100% of principal (excluding final Interest Payment). The Notes are senior unsecured obligations of Marex and carry Marex credit risk.
Marex Group plc director Assi Georges reported an equity award. On June 9, 2026, he was granted 2,070 Ordinary Shares at a price of $0.00 per share as a restricted share award. The filing notes these awards are contingent rights that convert into one Ordinary Share each upon vesting and settlement, giving him 2,070 shares reported as directly owned after the grant.
Schweinitz Konstantin Graf von reported acquisition or exercise transactions in this Form 4 filing.
Marex Group plc director Schweinitz Konstantin Graf von received an equity grant of 2,070 restricted share awards, each representing a contingent right to one ordinary share upon vesting and settlement. Following this grant, he directly holds 26,165 ordinary shares of Marex Group plc.
Ing Sarah reported acquisition or exercise transactions in this Form 4 filing.
Marex Group plc director Ing Sarah reported a grant of 2,070 ordinary shares in the form of restricted share awards. The awards were granted at a price of 0.0000 per share and represent a contingent right to receive one ordinary share per award upon vesting and settlement.
Following this grant, Ing Sarah holds 10,895 ordinary shares directly and 535 ordinary shares indirectly through a spouse. The filing reflects a compensation-related share award rather than an open-market purchase or sale.
Pietrowicz John W. reported acquisition or exercise transactions in this Form 4 filing.
Marex Group plc director Pietrowicz John W. received a grant of 2,070 Ordinary Shares as a restricted share award. The shares were awarded at no cash cost and are subject to vesting and settlement conditions. Following this compensation-related award, he directly holds 23,771 Ordinary Shares in total.